Predicting benefit from anti-angiogenic agents in malignancy
- 13 July 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 6 (8), 626-635
- https://doi.org/10.1038/nrc1946
Abstract
A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.Keywords
This publication has 59 references indexed in Scilit:
- Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal CancerClinical Cancer Research, 2006
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Biomarkers in Cancer Staging, Prognosis and Treatment SelectionNature Reviews Cancer, 2005
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 BlockadeClinical Cancer Research, 2005
- Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsAnnals of Oncology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999